A second meta-analysis identified 79 phase II/III studies, including post-menopausal women, with HR+/HER2− BC, whose disease progressed after first-line treatment with AI or ET, and explored the CDK4/6 inhibitors or PI3K/AKT/mTOR inhibitors in association with fulvestrant. This evidence concerns the gene ERBB2 and breast cancer.